Drug Optimisation and Safety Evaluation (DOSE) – unit
At VIVO BIO TECH, we deliver specialized preclinical services designed to meet the diverse demands of the pharmaceutical industry. Our comprehensive service suite encompasses all stages of preclinical drug development, from IND and NDA-enabling studies to impurity qualification, biodistribution, and bridging studies, each essential for streamlined regulatory submissions. Our expertise extends across safety evaluation, with specialized services in DMPK, genetic toxicology, mammalian toxicology, and meticulous formulation and bioanalysis, including method development and validation.
Our scientific team, led by seasoned experts, consistently ensures successful and timely project completions. We also support a wide array of functions, including Discovery/Medicinal Chemistry, Custom Synthesis, Process R&D, and scalable operations at our state-of-the-art Chemistry facility.
VIVO BIO TECH’s talented scientists bring extensive experience in drug discovery and regulatory services, with a profound understanding of disease biology that allows for the design of clinically relevant disease models. We offer flexible service models customized to meet our clients’ unique needs, ensuring quick turnaround, clear communication, and transparency throughout the process
As a global leader among Contract Research Organizations (CRO), VIVO BIO TECH has a proven track record of guiding pharma companies, particularly emerging firms, from initial concept to commercialization. We partner with over 500 clients worldwide, often deploying full-time equivalent (FTE) scientists in numbers that exceed those of our clients’ own teams. Our workforce includes over 200 highly qualified employees, with a notable number holding PhDs.
Our laboratory is equipped for various pharma-specific testing needs, including but not limited to:
